Giant Biogene Holding Co., Ltd.

HKSE 2367.HK

Giant Biogene Holding Co., Ltd. EPS (Diluted) for the year ending December 31, 2023: USD 0.21

Giant Biogene Holding Co., Ltd. EPS (Diluted) is USD 0.21 for the year ending December 31, 2023, a 46.79% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Giant Biogene Holding Co., Ltd. EPS (Diluted) for the year ending December 31, 2022 was USD 0.14, a 7.42% change year over year.
  • Giant Biogene Holding Co., Ltd. EPS (Diluted) for the year ending December 31, 2021 was USD 0.13, a 3.97% change year over year.
  • Giant Biogene Holding Co., Ltd. EPS (Diluted) for the year ending December 31, 2020 was USD 0.13, a 58.12% change year over year.
  • Giant Biogene Holding Co., Ltd. EPS (Diluted) for the year ending December 31, 2019 was USD 0.08.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
SV Wall Street
HKSE: 2367.HK

Giant Biogene Holding Co., Ltd.

CEO Mr. Jianya Yan
IPO Date Nov. 4, 2022
Location China
Headquarters No. 1855, Shanglin Yuan
Employees 1,512
Sector Consumers Staples
Industries
Personal Care Biotechnology Cosmetics Dental Care Eyewear Luxury Goods Pharmaceuticals Plastics
Description

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It also manufactures rare ginsenosides technology-based functional foods; and offers medical devices. The company offers its functional skincare products, medical dressings, and functional foods primarily under the Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan brands. Giant Biogene Holding Co., Ltd. was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.

StockViz Staff

February 3, 2025

Any question? Send us an email